Cooperative Agreement IDSEP230060

The National Cancer Institute has awarded a $275,627 Project Grant to Link Biosystems Inc., a self-certified small disadvantaged business and for-profit organization, to develop the ONXPANSION bioreactor workflow. This workflow aims to enable efficient expansion of patient-derived induced pluripotent stem cells into clinically relevant cell doses to support autologous cell therapy applications. The grant supports efforts to de-risk the utility of Link Biosystems' bioreactor technology for...

The National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, awarded a $349,746 Project Grant to Cisterna Biologics, Inc., a biotechnology company based in Oceanside, California. The goal of this 1-year Phase I SBIR grant is to develop an innovative platform for synthesizing high-quality, purified mRNA with minimal contaminants such as double-stranded RNA, long RNA, and short truncated RNA. These impurities can provoke immune responses and...

The National Institute of General Medical Sciences (NIGMS) awarded a $305,892 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Dotquant LLC, a biotechnology research and development company, to develop a new in vitro transcription kit for high-yield synthesis of chemically modified RNA. The project aims to combine the benefits of wild-type T7 RNA polymerase, which has high efficiency and low cost, with the ability of mutant T7 RNA polymerases to...

The National Institute of General Medical Sciences (NIGMS) awarded Attogene Corporation, a biotechnology company based in Austin, Texas, a $229,975 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to develop a rapid, portable, and sensitive test for detecting ribonucleases (RNases). The grant supports the company's efforts to create a novel lateral flow assay prototype that can quickly identify RNase contamination, which is critical for ensuring quality...

The National Cancer Institute (NCI) awarded a $825,857 Cooperative Agreement under the Cancer Cause and Prevention Research program (CFDA 93.393) to Health Research, Inc. at Roswell Park Comprehensive Cancer Center. The goal of this 5-year award is to catalyze collaboration across the Cancer Immunoprevention Network (CIP-NET) and manage, integrate, and disseminate the data and resources generated by the network. Key objectives include fostering a collaborative research community, providing...

Partillion Bioscience Corp. was awarded a $659,037 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences to develop reagent products enabling high-throughput screening and selection of single cells based on secreted bio-products. Under the Biomedical Research and Research Training program (CFDA 93.859), Partillion plans to transition its lab-on-a-particle technology—highlighted as a 2020 SLAS Innovation Award winner—into the first reagent product...

The National Center for Advancing Translational Sciences (NCATS) awarded a $275,000 Project Grant (CFDA 93.350) to Nectagen Inc. to develop bioprocess-compatible, second-generation nanoclamp affinity resins for the efficient purification of plasma-based therapeutic proteins. The goal is to identify panels of nanoclamps to 5 industrially relevant plasma-based therapeutics, select lead candidates, and optimize the resins for maximum recovery and purity from plasma samples. This project aims to...

This National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) Project Grant award of $285,444, effective August 15, 2025 through August 14, 2026 (CFDA 93.350), aims to develop recombinant human enzyme panels representing genetic variants of drug-metabolizing enzymes present in the U.S. patient population. The goal is to bridge shortcomings in current in vitro drug metabolism testing, which typically relies on liver microsomes or hepatocytes from...

Cache DNA, Inc. was awarded a $255,819 National Science Foundation Technology, Innovation, and Partnerships Project Grant to develop a massively scalable storage solution for nucleic acids using barcoded polymer packets. The goal of the Phase I Small Business Innovation Research project is to establish a low-cost approach to maintaining the integrity of nucleic acids, including animal, bacterial, and viral genomes, at room temperature for decades without requiring energy-intensive freezing or...

This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...